Glucose-stimulated and pancreatic islet ␤ cell-specific expression of the insulin gene is mediated in part by the C1 DNA-element binding complex, termed RIPE3b1. In this report, we define the molecular weight range of the protein(s) that compose this ␤ cell-enriched activator complex and show that protein phosphatase treatment inhibits RIPE3b1 DNA binding activity. Fractionation of ␤ cell nuclear extracts by sodium dodecyl sulfate-polyacrylamide gel electrophoresis indicated that RIPE3b1 binding was mediated by a protein(s) within the 37-49-kDa ranges. Direct analysis of the proteins within the RIPE3b1 complex by ultraviolet light cross-linking analysis identified three binding species of approximately 51, 45, and 38 kDa. Incubating ␤ cell nuclear extracts with either calf alkaline phosphatase or a rat brain phosphatase preparation dramatically reduced RIPE3b1 DNA complex formation. Phosphatase inhibition of RIPE3b1 binding was prevented by sodium pyrophosphate, a general phosphatase inhibitor. We discuss how changes in the phosphorylation status of the RIPE3b1 activator may influence its DNA binding activity.
Insulin is an essential regulator of metabolism. This hormone, which is synthesized by the ␤ cells of the islets of Langerhans, increases the storage of glucose, fatty acids, and amino acids through its actions in liver, adipose tissue, and muscle. Experiments performed in vivo with transgenic animals have established that the cis-acting elements controlling ␤ cell-selective expression are located within the mammalian insulin enhancer region, which is found between nucleotides Ϫ340 to Ϫ91 relative to the transcription start site (1, 2) . Several key control elements within this region have been identified by detailed mutagenesis strategies, including the C2 (Ϫ317/Ϫ311 base pairs (bp) 1 ) (3), A3 (Ϫ201 to Ϫ196 bp) (4, 5) , C1/RIPE3b (Ϫ118 to Ϫ107 bp) (6, 7) , and E1 (Ϫ100 to Ϫ91 bp) (8 -11) elements. The core sequence motifs for each of these elements are also found within the transcription unit of all characterized mammalian insulin genes (12) suggesting that similar transcriptional regulatory mechanisms are utilized in control. Mutations that decrease the binding affinity of the A3, C1/RIPE3b, and E1 activators reduce both glucose-regulated and ␤ cell type-specific transcription from insulin gene reporter constructs (13) (14) (15) (16) (17) .
The activator of insulin C2 element-stimulated transcription is PAX6 (3), a member of the Pax transcription factor family. Proteins in this family all contain a paired box bipartite DNA binding domain, although PAX6 also has a homeodomain. The PDX-1 homeodomain protein (also known as IPF-1, STF-1, and IDX-1 (18 -20) ) appears to be the principal regulator of A3 element-activated expression (5, 17, 20) . The E1 activator is a heterodimer, composed of proteins in the basic helix-loop-helix family that are enriched in islets (BETA2 (21) ) and generally distributed (HEB (22) and E2A (23) (24) (25) ). Gene ablation experiments performed in mice on each of these factors has also clearly established a key role for the islet-enriched transcription factors (i.e. PAX6, PDX-1, and BETA2) in pancreatic development. Thus, the expression of PDX-1 in precursor cells appears to be essential for the development of both the endocrine and exocrine compartments of the pancreas (26, 27) , whereas BETA2 (28) and PAX-6 (3, 29) act at a later stage of pancreatic development, involving islet cell formation and maintenance (BETA2 (28) ) as well as differentiation to specific islet cell types (PAX-6) (3, 29) .
In contrast to the C2, A3, and E1 activators, little is known about the protein(s) involved in C1 element stimulation. Two distinct factor-DNA complexes are formed with the C1 element in the gel mobility shift assay, termed RIPE3b1 and RIPE3b2 (6) . The RIPE3b1 complex appears to be uniquely present in ␤ extracts, whereas RIPE3b2 is widely distributed (6) . The RIPE3b2 complex is composed of at least three subunits, p58, p62, and p110 (30) .
The importance of the RIPE3b2 activator in insulin gene expression is unclear, although it is not believed to have a role in ␤ cell-specific activation (6, 30) . However, RIPE3b1 does appear to play a key role in regulating insulin transcription. Thus, the C1 element mediates glucose-induced transcription of transfected insulin-driven reporter constructs in both ␤ cell lines (7, 16) and islets (15) , and stimulation is also associated with increased RIPE3b1 DNA binding (7, 16) . The binding of RIPE3b1 is also decreased in parallel with the reduction in insulin gene transcription when ␤ cells are chronically exposed to supraphysiological glucose concentrations (31) (32) (33) (34) . Interestingly, glucose appears to regulate PDX-1 binding levels in parallel with RIPE3b1 (14, 17, 31, (33) (34) (35) (36) . The observation that the phosphorylation level of PDX-1 is induced in glucose-stimulated ␤ cells upon activation of DNA binding (36 -38) suggested that this post-translational modification mechanism might also control the binding potential of RIPE3b1.
To address this issue, we determined the protein composition of the RIPE3b1 activator complex. Our analysis of sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)-fractionated ␤ cell nuclear extracts revealed that RIPE3b1 binding was mediated by a protein(s) of roughly 43 kDa. Several proteins (i.e. 51, 45, and 38 kDa) within this molecular mass range were also independently shown to be within the RIPE3b1 complex by ultraviolet light (UV) crosslinking analysis. In addition, we demonstrated that protein phosphatase treatment reduced RIPE3b1 binding activity in ␤ cell nuclear extracts. These results suggest that phosphorylation mechanisms are also important in controlling RIPE3b1 activator function.
MATERIALS AND METHODS
DNA Constructs-The Ϫ238WT CAT plasmid contains sequences from Ϫ238 to ϩ2 bp of the rat insulin II enhancer/promoter region linked to the chloramphenicol acetyltransferase (CAT) reporter gene (39) . The C1/RIPE3b1 element mutants were generated in Ϫ238WT CAT using the QuikChange Site-directed mutagenesis kit (Stratagene). The following oligonucleotides were used: Ϫ114 Mutant, 5Ј GTTTG-GAAACTGCAGATTCAGCCCCTCTGGC 3Ј, Ϫ108/Ϫ107 Mutant, 5Ј GAAACTGCAGCTTCAGAACCTCTGGCCATCTGC 3Ј. The mutated nucleotides are underlined. Each of the constructs was verified by DNA sequencing.
Cell Culture and Transfection-Monolayer cultures of insulin producing ␤TC-3 (40), HIT T-15 2.2 (12), INS-1 (33) , and MIN6 (41) cells as well as AR42J (rat acinar cells) (42) , ␣TC-6 (glucagon-producing mouse islet ␣ cells) (39) , HeLa (human cervical carcinoma) (10), NIH3T3 (mouse fibroblasts) (43), H4IIE (rat hepatoma) (44) , and baby hamster kidney (BHK) (6) cells were maintained as described previously. The glucose concentration within the culture medium was approximately 25 mM. Glucose-treated MIN6 cells were first washed twice with phosphate-buffered saline and then cultured in medium containing 1 mM glucose for 12 h, before growing the cells in 1, 3, or 20 mM glucosesupplemented medium for 24 h. The insulin:CAT constructs were transiently transfected by the calcium phosphate coprecipitation (HIT T-15; 2 ϫ 10 6 cells) (7) or LipofectAMINE (␤TC-3; 1 ϫ 10 6 cells) procedures (LipofectAMINE Reagent, Life Technologies, Inc.). The precipitates used for the HIT T-15 transfections (13.5 g total) contained 2.5 g of Ϫ238CAT and pRSVLUC, whereas 1 g of each plasmid (2 g total) was used with ␤TC-3 cells. The Rous sarcoma virus (RSV) enhancer-driven luciferase (LUC) expression plasmid, pRSVLUC (45) , was used as a recovery marker. HIT T-15 cells were treated with 20% glycerol (2 min) 4 h after the addition of the calcium phosphate DNA precipitate. Extracts were prepared 40 -48 h after transfection and LUC and CAT enzymatic assays performed as described by DeWet et al. (45) and Nordeen et al. (46) , respectively. The CAT activity from the reporter construct was normalized to the LUC activity of the cotransfected internal control plasmid. Each experiment was carried out at least three times.
Electrophoretic Mobility Shift Assays-Nuclear extracts were prepared as described by Schreiber et al. (47) , except that 1 mM phenylmethylsulfonyl fluoride was included in the nuclear resuspension buffer. Binding reactions (20 l) were conducted in the binding buffer (10 mM HEPES (pH 7.4), 100 mM NaCl, 2 mM dithiothreitol, 1 g of poly(dI-dC), 10% (v/v) glycerol). Approximately 15 g of extract protein was used per gel mobility shift sample. Each of the rat insulin II Ϫ126/Ϫ101-bp oligonucleotides used to detect RIPE3b1/C1 element binding were first subcloned into pGEM7 (Stratagene). Excised, purified double-stranded fragments were used in the binding reactions. The Ϫ126/Ϫ101-bp probe was labeled with [␣-32 P]dATP by incubation with the Klenow fragment of Escherichia coli DNA polymerase I. The conditions for the competition analyses were the same, except that a 200-fold excess of the specific competitor DNAs was included in the mixture prior to addition of extract. The double-stranded oligonucleotides corresponded to the following: wild type, Ϫ126 TGGAAACTG-CAGCTTCAGCCCCTCTG Ϫ101; Ϫ114 Mutant, Ϫ126 TGGAAACTG-CAGATTCAGCCCCTCTG Ϫ101; Ϫ111 Mutant, Ϫ126 TGGAAA-CTGCAGCTTAAGCCCCTCTG Ϫ101; Ϫ108/Ϫ107 Mutant, Ϫ126 TG-GAAACTGCAGCTTCAGAACCTCTG Ϫ101. The mutated nucleotides are underlined. After incubating the reactions at room temperature for 20 min, the binding complexes were resolved by electrophoretic separation on a 6% non-denaturing polyacrylamide gel using high ionic strength polyacrylamide gel electrophoresis conditions (7). The gel was then dried, and the labeled DNA-protein complexes were localized by autoradiography.
In Situ UV Cross-linking-The UV cross-linking experiments were conducted essentially as described by Shieh and Tsai (6) . The gel mobility shift binding reaction was scaled up by 10-fold and conducted in a 96-well plate as described above. The plastic-wrapped plate was irradiated with 254 nm UV light at a distance of 1 cm at 4°C for 45 min. The complexes were resolved on a 6% non-denaturing polyacrylamide gel. After locating the binding complexes by brief autoradiography, the RIPE3b1 complex was specifically excised, and the gel piece was minced and mixed with 200 l of elution buffer (50 mM Tris-HCl (pH 7.4), 0.2 mM EDTA, 0.1% SDS, 1ϫ protease inhibitor mixture solution (Roche Molecular Biochemicals)) and rotated at 4°C overnight. The eluate was mixed with 1ϫ SDS loading buffer, boiled, and loaded onto a 10% SDS-polyacrylamide gel. After electrophoresis, the gel was dried and subjected to autoradiography. The molecular size of the protein-C1 element DNA complexes were determined by comparison with Colored Rainbow protein molecular weight markers (Amersham Pharmacia Biotech) run in the same gel.
SDS-PAGE Fractionation-␤TC-3 cell nuclear extract (30 g) was separated on a 10% SDS-polyacrylamide gel and then electrotransferred onto an Immobilon polyvinylidene fluoride membrane (Millipore). The ␤TC-3 extract lane was cut horizontally into 4-mm slices to represent different molecular weight fractions. The proteins from each fraction were eluted at 4°C in 60 l of elution buffer (10 mM Tris-HCl (pH 7.4), 100 mM NaCl, 10% (v/v) glycerol, 1 mM EDTA, 2 mM dithiothreitol, 0.1 mg/ml bovine serum albumin, 1ϫ protease inhibitor mixture solution, 1% (v/v) Triton X-100) for 4 h (48). The molecular sizes of the protein-C1 element DNA complexes were determined by comparison with Colored Rainbow protein molecular weight markers. Each fraction was analyzed for insulin Ϫ126/Ϫ101-bp binding activity in the gel mobility shift assay.
In Vitro Phosphatase Treatment-␤TC-3 nuclear extracts were prepared as described above except that 10 mM sodium fluoride and 1 mM sodium orthovanadate were added to the final resuspension buffer. Three micrograms (20 l total reaction volume) of the ␤TC-3 nuclear extract (or Immobilon fraction 6) was incubated at 30°C for 20 min in 1ϫ phosphatase buffer (20 mM Tris-HCl (pH 7.4), 1 mM dithiothreitol, 0.1 mM EGTA, 2 mM MgCl 2 , 1ϫ protease inhibitor mixture solution) with different concentrations of calf intestinal alkaline phosphatase (20 units/l (Promega)) or a rat brain phosphatase catalytic subunit mixture in the presence or absence of 50 mM sodium pyrophosphate. The brain protein phosphatase catalytic subunit-enriched preparation was prepared by ethanol precipitation of a rat brain soluble extract (49) . This extract was shown to contain catalytic subunits of PP1 and PP2A, the major divalent cation-independent protein phosphatases in mammalian tissues; the unit phosphatase activity per microliter was 360 fmol/min using glycogen phosphorylase as substrate, of which greater than 95% of the activity was inhibited by 2.5 M okadaic acid (49) . After phosphatase treatment, 25 l of 2ϫ binding buffer was added and the sample analyzed for insulin Ϫ126/Ϫ101-bp probe binding.
RESULTS

The RIPE3b1 Activator Complex Appears to Be Unique to
Islet ␤ Cells-RIPE3b1 complex binding was only detected in HIT T-15 ␤ extracts, when gel mobility shift binding assays were performed with nuclear extracts prepared from a ␤ (HIT T-15) and two non-␤ cell lines (BHK, HeLa) (6). To assess more generally the distribution of the RIPE3b1 activator, binding experiments were performed with the Ϫ126/Ϫ101-bp C1 element probe and nuclear extracts prepared from several ␤ (␤TC-3, MIN-6, INS-1, and HIT T-15) and non-␤ cell lines, including islet ␣ (␣TC-6), exocrine pancreas (AR42J), liver (H4IIE), and fibroblast (NIH3T3) cells. The RIPE3b1 complex was detected in each of the ␤ cell nuclear extracts but in none of the non-␤ extracts (Fig. 1A) . In addition, RIPE3b1 binding activity was also inducible at physiologic glucose concentrations in MIN6 cells (Fig. 1B) . Thus, RIPE3b1 binding increased significantly in cells cultured in 3 and 20 mM glucose when compared with 1 mM (Fig. 1B) . RIPE3b1 binding is similarly regulated by glucose in HIT T-15 (7), ␤TC-3 (16), and ␤TC-6 (16) cells. The change in RIPE3b1 activity appears to be specific as binding to the insulin E1 activator (7, 16) and ubiquitous major late transcription factor (7, 16, data not shown) was unchanged under these conditions. Furthermore, a mutant that prevented RIPE3b1 binding reduced glucose-inducible insulin reporter gene activity in transfected MIN6 (data not shown), HIT T-15 (7), ␤TC-3 (16), and ␤TC-6 (16) cells. Together, these results strongly suggest that RIPE3b1 is a ␤ cell-specific, physiologically responsive, transcriptional regulator of the insulin gene.
Identification of the Sequences within the Insulin C1 Element That Control RIPE3b1 Activation-In order to understand more fully the role of the RIPE3b1 in C1 element-mediated transcriptional stimulation of the insulin gene, experiments were performed to identify the RIPE3b1 complex:C1 element contact sites relevant to activation and binding. Methylation interference analysis has shown that RIPE3b1 strongly contacts the bottom strand Gs in the C1 element at Ϫ111, Ϫ108, and Ϫ107, as well as the G at Ϫ114 weakly (6) . A mutation in the region of the Ϫ111G prevents C1 element activation and RIPE3b1 binding (6); two nucleotides were modified in this mutant (Ϫ112/AG/Ϫ111 to Ϫ112/GC/Ϫ111; Fig. 2 ). To define more comprehensively the role of the G nucleotide contacts in RIPE3b1 function, site-directed mutations within the nucleotides at Ϫ114, Ϫ108, and Ϫ107 were constructed within the context of an insulin enhancer/promoter-driven CAT reporter construct spanning the Ϫ238 to ϩ2-bp region of the rat insulin II gene. Their effect on activation was compared with the Ϫ112/GC/Ϫ111 mutant and the wild type Ϫ238CAT construct in transfected HIT T-15 and ␤TC-3 cells (Fig. 2B) . The results clearly show that G mutations within the strong RIPE3b1 contact sites at Ϫ111, Ϫ108, and Ϫ107 bp reduce Ϫ238 CAT activity, whereas the weak interaction site at Ϫ114 bp has no effect.
The gel shift assay was used to determine the importance of the G residues at nucleotides Ϫ114, Ϫ111, Ϫ108, and Ϫ107 in RIPE3b1 binding in ␤TC-3 cell nuclear extracts. The specificity of binding was determined in competition assays in which wild type and mutant alleles of the C1 element were used as competitors. The pattern of competition with the various alleles of C1 was as predicted (Fig. 3) . Thus, mutant forms that reduce insulin reporter gene transcription in transfected cells are not efficient competitors for formation of the RIPE3b1 complex in vitro. Neither the Ϫ111 nor Ϫ108/Ϫ107 mutant form of C1 competed well, whereas the Ϫ114 mutant competed as effectively as the wild type. The Ϫ112/GC/Ϫ111 mutant competitor also had no effect on RIPE3b1 binding levels (6, 7, 31), indicating that only the G residue at nucleotide Ϫ111 within this mutant was essential in binding. The RIPE3b2 complex was not detected in our gel shift reaction assays due to the nonspecific poly(dI-dC) competitor concentration in the binding reaction ( Fig. 3; data not shown) . Analogous results were obtained with the RIPE3b1 complex formed in HIT T-15, MIN6, and INS-1 extracts (data not shown). Together, these data strongly suggest that the G residues at Ϫ111, Ϫ108, and Ϫ107 are critical for binding and activation of a protein(s) contained within the ␤ cell-specific RIPE3b1 complex.
The RIPE3b1 Complex Contains a 43-kDa Protein(s)-
To estimate the size of the RIPE3b1 DNA-binding complex, ␤TC-3 nuclear extracts were separated by SDS-PAGE and transferred onto an Immobilon polyvinylidene fluoride membrane, which was cut into slices, and the fractionated proteins were eluted. , and H4IIE) were used in the gel mobility shift assay. Binding reactions performed with a 200-fold molar excess of unlabeled wild type and mutant competitor to probe were used to identify the RIPE3b1 and nonspecific (denoted with an asterisk) complexes (see Fig. 3) . B, RIPE3b1 binding is induced by glucose. Equal concentrations of MIN6 nuclear extract (10 g) prepared from cells grown in either 1, 3, or 20 mM glucose were analyzed for C1 element binding.
FIG. 2. Effect of point mutations within the C1 element on
؊238CAT expression in ␤ cells. A, sequences of the C1 region (Ϫ118 to Ϫ107 bp) in the rat insulin II gene. The underlined G residues were shown by methylation interference analysis to be sites of contact with the RIPE3b1 activator (6) . The Gs at nucleotides Ϫ114, Ϫ108, and Ϫ107 were changed to Ts; the Ϫ112/AG/Ϫ111 was changed to GC in the Ϫ112/Ϫ111 Mutant (6). The specific inhibitory effect on insulin:CAT activity and RIPE3b1 binding of the Ϫ112/Ϫ111 Mutant in ␤ cells has been described (6, 7, 31) . B, relative activity of the C1 element mutants of Ϫ238CAT in HIT T-15 and ␤TC-3 cells. The results are presented as the ratio of the normalized activity produced from C1 Mutant Ϫ238CAT to the normalized activity produced by the Ϫ238WTCAT plasmid Ϯ S.D. WT, wild type.
C1 element binding was then measured in each of the renatured fractions. The binding activity in fractions 6 and 7 comigrated with the RIPE3b1 complex found in unfractionated ␤TC-3 extracts (Fig. 4A) . No change in the mobility of this complex was observed when extracts from other fractions were combined with either fraction 6 or 7 (data not shown), suggesting that these fractions contain the principal RIPE3b1-binding protein(s). Importantly, the binding specificity of these fractions also corresponds to RIPE3b1, as fraction 6 binding was unaffected in competition assays with mutants (i.e. Ϫ111 mutant) that disrupted RIPE3b1 binding but eliminated by the wild type or Ϫ114 mutant (Fig. 5, data not shown) . The molecular mass range of the proteins in fractions 6 and 7 was 37.1 to 49.1 kDa. These results indicate that the RIPE3b1 activator complex is composed of one or more proteins of approximately 43 kDa.
The RIPE3b1 Binding Complex Contains Several Proteins within the 43-kDa Range-To define more precisely the protein composition of the RIPE3b1 complex, we performed in situ UV cross-linking analysis. The ␤TC-3 binding reactions were first irradiated with UV light, and then the RIPE3b1 complex was excised after electrophoresis on a non-denaturing polyacrylamide gel. The cross-linked RIPE3b1 protein(s):C1 element species were separated by SDS-PAGE and visualized by autoradiography. The analysis revealed at least three C1-binding polypeptides, with apparent molecular masses 70.7 Ϯ 0.8, 65.3 Ϯ 0.7, and 58.3 Ϯ 3.3 kDa (Fig. 6) . The specificity of these interactions with the C1 element was confirmed by the fact that the wild type competitor, but not a binding defective mutant (i.e. Ϫ111 mutant), could prevent their formation (Fig.  6 ). In addition, these complexes were not detected in the absence of UV irradiation or when either the labeled Ϫ111 or Ϫ108/Ϫ107 mutant oligonucleotides were used as probes (data not shown). Similar results were obtained using HIT T-15 and MIN6 nuclear extracts (data not shown). Upon subtraction of the molecular mass of the C1 DNA probe (approximately 20 kDa), the sizes of the cross-linked polypeptides were calculated to be 51, 45, and 38 kDa, which is in agreement with the molecular weight range of the SDS-PAGE separated proteins in fractions 6 and 7.
Protein Phosphatase Treatment Decreases RIPE3b1 Binding
Activity-RIPE3b1 and PDX-1 binding activities are induced at glucose levels that potentiate insulin gene transcription and insulin secretion within ␤ cells (13) (14) (15) (16) ). Activation appears to require phosphorylation of PDX-1 (36 -38), a post-translational modification mechanism that controls the activation domain and DNA binding domain potential of a number of other transcription factors (50, 51) .
To determine if the phosphorylation status of RIPE3b1 influences DNA binding, ␤TC-3 extracts were incubated in the absence or presence of increasing amounts of calf intestinal alkaline phosphatase (CIAP). RIPE3b1 DNA binding activity was inhibited by CIAP treatment in a dose-dependent manner (Fig. 7A) . The effect of CIAP on RIPE3b1 binding was essentially blocked by coincubating the enzyme with 50 mM sodium pyrophosphate, a general phosphatase inhibitor. However, the mobility of the RIPE3b1 binding complex was more diffuse under these conditions (Fig. 7A) , which could result from the phosphatase and/or proteolysis changing the mobility of the RIPE3b1/C1-binding protein(s) in the extract. Since the binding activity of the generally distributed adenovirus-5 major late transcription factor was unaffected in these extracts (data not shown), it is unlikely that the change in RIPE3b1 binding activity results from proteolysis.
Further evidence supporting that this was a specific effect of CIAP was established by performing the reactions with a distinct protein phosphatase preparation from rat brain. RIPE3b1 activity in ␤TC-3 extracts was also reduced in a dose-dependent fashion under these conditions (Fig. 7B) . However, in contrast to CIAP, 50 mM sodium pyrophosphate treatment completely blocked the phosphatase activity in the brain preparation. In addition, the CIAP (data not shown) or brain phosphatase(s) (Fig. 7C) reduced RIPE3b1 binding activity in SDS-PAGE fraction 6 when the reaction was conducted in the absence, and not presence, of sodium pyrophosphate. Treatment with more specific phosphatase inhibitors (i.e. microcystin and okadaic acid) also reduced brain phosphatase preparation-mediated inhibition (data not shown). These results suggest that the phosphorylation state of a protein(s) in the RIPE3b1 complex controls the DNA binding ability of this activator.
DISCUSSION
The C1 element contributes to both tissue-specific and glucose-regulated expression of the insulin gene. Gel shift analysis revealed that two separate complexes, RIPE3b1 and RIPE3b2, bound to the C1 element. Notably, the RIPE3b1 complex was uniquely formed in ␤ cell extracts and also regulated by glucose in parallel with insulin gene expression. These observations strongly suggest that RIPE3b1 is critical for C1-regulated transcription. In this paper, we have shown by SDS-PAGE fractionation and UV cross-linking analysis that the RIPE3b1 complex in ␤ cells is composed of proteins of approximately 43 kDa. Protein phosphatase treatment was also shown to inhibit RIPE3b1 binding. These results imply that the phosphorylation state of a protein(s) within the RIPE3b1 complex is critical to DNA binding and, as a consequence, activation.
The RIPE3b1 complex was found to contain DNA-binding proteins from 37.1 to 49.1 kDa (Fig. 4) , presumably represented by the UV cross-linked proteins of roughly 38, 45, and 51 kDa specifically bound to the C1 element (Fig. 5) . Because the DNA binding activity of RIPE3b1 was reduced by CIAP or brain phosphatase treatment, it is unclear whether modified forms of a single protein or several distinct proteins reflect the size difference of the C1-binding proteins. Protein phosphorylation has been shown to induce a change in molecular weight within this range in a number of different proteins; most notably, PDX-1 is shifted from 31 to 46 kDa by phosphorylation (38) . In contrast, UV cross-linking analysis performed on the ubiquitously distributed RIPE3b2 complex revealed a larger and broader molecular mass range of proteins (i.e. 58, 62, and 110 kDa) (30) . The p110 subunit of RIPE3b2 is Smbp-2, a protein with potential helicase motifs and a transcription activation domain (30) . Importantly, the differences in molecular weight between the various protein:C1 element binding species indicates that RIPE3b1 and RIPE3b2 do not have common subunits.
The sensitivity of RIPE3b1 to both CIAP and brain phosphatase treatment clearly indicates that it is similar to PDX-1, in that phosphorylation events within the ␤ cell control the DNA binding potential of each protein. PDX-1 is rapidly phosphorylated in high glucose-treated cells (36) . Phosphorylation appears to convert PDX-1 from an inactive, cytoplasmic 31-kDa form, which is found under low glucose conditions, to the active 46-kDa nuclear protein of high glucose-stimulated ␤ cells (38) . Rafiq et al. (52) also found that glucose influences the cellular localization of PDX-1, although their results indicate that the inactive form is on the periphery of the nucleus. Upon isolation of the gene(s) (cDNA) for RIPE3b1, it will be of interest to 
FIG. 7.
Protein phosphatase treatment inhibits RIPE3b1 binding activity. ␤TC-3 nuclear extracts were preincubated with CIAP (A) or a brain phosphatase preparation (BPP) (B) in the absence (Ϫ) or presence of 50 mM sodium pyrophosphate (NaPi). C, ␤TC-3 nuclear extracts (␤TC-3 NE) and SDS-PAGE fraction 6 (fraction 6) treated with BPP. RIPE3b1 binding in the treated extracts was analyzed by gel shift analysis using the Ϫ126/Ϫ101-bp probe. The arrow points to the RIPE3b1 band. determine if activation is also dynamically regulated by changes in its phosphorylation status within the ␤ cell.
Gene ablation experiments performed in mice on the isletenriched PAX6 (3, 28) , PDX-1 (26, 27) , and BETA2 (28) transcription factors have clearly demonstrated that these proteins not only play a role in insulin gene transcription but also pancreatic development. In addition, heterozygous human mutant carriers of PDX-1 (53) and BETA2 (54) also contribute to the pathogenesis of diabetes, a disease at least partially caused by a failure of the ␤ cell to provide insulin in amounts sufficient to maintain glucose homeostasis. These findings illustrate how the identification and characterization of transcriptional regulators of islet-enriched products, like insulin, are essential for our understanding of the disease process affecting the ␤ cell. We are currently working toward isolating the gene(s) encoding RIPE3b1, which we believe will be essential in cell-specific and nutrient regulation of insulin mRNA production.
